When Merck moseyed into the Lone Star State as part of a global IT restructuring, it pitched a robust hiring plan in exchange for nearly $ 7 million in tax breaks and grants. Now, after Merck pulled back the reins on its Austin plans, those incentives have dried up. Merck is walking away from incentive… Read More: Merck abandons $7M in grants for long-term IT hiring plan… »
Merck hasn’t exactly made a fortune on its $ 9.5 billion Cubist Pharmaceuticals buyout, but now, a next-gen antibiotic it acquired in that deal has a brand-new indication that could help jump-start sales. On Monday, the FDA approved that drug, Zerbaxa, to treat adults with hospital-acquired and ventilator-associated pneumonia. It’s an add-on to Zerbaxa’s original approvals—to treat complicated… Read More: Years after Cubist buyout, Merck scores a new Zerbaxa indication.… »
by CS Chen Merck & Co., Inc. (NYSE: MRK), one of the largest pharmaceutical companies in the world, which is known for its treatments like Gardasil (human papilloma virus), Propecia (baldness), and Zocor (cholesterol) detailed its global structuring program on Friday. The company’s integration plans aim at its research and development, business operations, and manufacturing. … Read More: Merck (NYSE: MRK) details integration plans »